

1 **The SARS-CoV-2 accessory factor ORF7a downregulates MHC class I surface expression**

2

3 Shuxuan Zheng^{a,#}, Hendrik de Buhr^{a,#}, Patrique Praest^a, Anouk Evers^a, Ingrid Brak-Boer^a, Mariëlle
4 van Grinsven^a, Ylenia Longo^b, Liset de Vries^a, Wilco Nijenhuis^c, Lukas C. Kapitein^c, Jeffrey M.
5 Beekman^d, Monique Nijhuis^a, Ingo Drexler^b, Emmanuel J. H. J. Wiertz^a, Robert Jan Lebbink^a

6

7 ^a*Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The*
8 *Netherlands.*

9 ^b*Institute for Virology, Düsseldorf University Hospital, Heinrich-Heine-University, Düsseldorf,*
10 *Germany.*

11 ^c*Cell Biology, Neurobiology and Biophysics, Department of Biology, Faculty of Science, Utrecht*
12 *University, Utrecht, The Netherlands; Centre for Living Technologies, Alliance TU/e, WUR, UU,*
13 *UMC Utrecht, Utrecht, The Netherlands.*

14 ^d*Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center*
15 *Utrecht, Utrecht, The Netherlands; Regenerative Medicine Center Utrecht, University Medical*
16 *Center, Utrecht, The Netherlands.*

17

18 *Correspondence: r.j.lebbink-2@umcutrecht.nl ([R.J. Lebbink](#)).

19 #Equal contribution

20

21 Keywords: SARS-CoV-2, ORF7a, MHC class I antigen presentation pathway, COVID-19, immune
22 evasion

23 **Abstract**

24 The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
25 resulted in over 500 million infections and more than six million deaths worldwide. Although the
26 viral genomes of SARS-CoV-1 and SARS-CoV-2 share high sequence homology, the clinical and
27 pathological features of COVID-19 differ profoundly from those of SARS. It is apparent that
28 changes in viral genes contribute to the increased transmissibility of SARS-CoV-2 and pathology
29 of COVID-19.

30 Cytotoxic T lymphocytes play a key role in the elimination of virus-infected cells, mediated by
31 recognition of virus-derived peptides that are presented on MHC class I molecules. Here, we
32 show that SARS-CoV-2 can interfere with antigen presentation thereby evading immune
33 surveillance. SARS-CoV-2 infection of monkey and human cell lines resulted in reduced cell-
34 surface expression of MHC class I molecules. We identified a single viral gene product, the
35 accessory factor open reading frame 7a (ORF7a), that mediates this effect. ORF7a interacts with
36 HLA class I molecules in the ER, resulting in ER retention or impaired HLA heavy chain (HC)
37 trafficking to the Golgi. Ultimately, these actions result in reduced HLA class I surface expression
38 on infected cells. Whereas ORF7a from SARS-CoV-2 reduces surface HLA class I levels, the
39 homologous ORF7a from the 2002 pandemic SARS-CoV-1 did not, suggesting that SARS-CoV-2
40 ORF7a acquired the ability to downregulate HLA-I during evolution of the virus. We identified a
41 single amino acid in the SARS-CoV-1 ORF7a luminal domain that, upon mutating to the
42 corresponding SARS-CoV-2 ORF7a sequence, induced a gain-of-function in HLA surface
43 downregulation. By abrogating HLA class I antigen presentation via ORF7a, SARS-CoV-2 may

44 evade host immune responses by inhibiting anti-viral cytotoxic T cell activity, thereby
45 contributing to the pathology of COVID-19.

46

47 **Introduction**

48 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the
49 current coronavirus disease 2019 (COVID-19) pandemic. Whereas common circulating
50 coronaviruses only induce mild illnesses in humans [1], pathology of COVID-19 is more severe.
51 Over the past twenty years, two additional zoonotic coronaviruses have emerged that cause
52 serious respiratory disease in humans: severe acute respiratory syndrome coronavirus (SARS-
53 CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV) [2]. Like SARS-CoV-1 and
54 MERS-CoV, SARS-CoV-2 is an enveloped positive-sense single-stranded RNA virus from the family
55 of *Coronaviridae* [3]. The SARS-CoV-2 genome consists of 14 open-reading frames (ORFs), that
56 encode multiple proteins with dedicated functions. ORF1a and ORF1b encode 16 non-structural
57 proteins (NSP1-NSP16) that comprise the replicase-transcriptase complex [4]. In addition, SARS-
58 CoV-2 encodes 13 ORFs at the 3' end of its genome, consisting of four structural and nine putative
59 accessory factors. The structural proteins encode constituents of the viral nucleocapsid, including
60 the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins [5]. The nine accessory
61 proteins are virulence factors involved in the pathogenicity of the virus [6]. Many of their specific
62 functions remain unknown, although it is likely that they impact the host response to virus
63 infection and as such contribute to the pathology of COVID-19.

64 The MHC class I antigen presentation pathway (in humans also referred to as the HLA class I
65 antigen presentation pathway) is an integral component of the host's immune defense to

66 counteract viral infections. Viruses depend on their host to facilitate infection and replication,
67 e.g. for viral protein synthesis. Upon viral protein synthesis, a fraction of these molecules are
68 processed by the proteasome to small peptides that are subsequently translocated to the ER
69 lumen by the transporter associated with antigen processing (TAP). There, they are loaded onto
70 MHC class I molecules and presented at the cell surface to circulating CD8⁺ cytotoxic T
71 lymphocytes (CTLs). Upon recognition of the MHC-I-peptide complex via their T cell receptor,
72 CTLs become activated and induce killing of the antigen-presenting cells by various effector
73 mechanisms [7]. To counteract this anti-viral activity, many viruses have evolved sophisticated
74 mechanisms to interfere with antigen presentation [8]. They e.g. inhibit MHC class I molecule
75 synthesis, induce their degradation via the proteasome, or avert peptide or MHC class I transport.
76 These activities ultimately reduce MHC class I antigen presentation on the cell surface, thereby
77 interfering with recognition by CTLs [8].

78 As CTLs play a key role in the elimination of virus-infected cells, we assessed whether SARS-CoV-
79 2 has evolved strategies to counteract these antiviral measures by interfering with the HLA class
80 I antigen presentation pathway. Indeed, our results suggest that the accessory factor open
81 reading frame 7a (ORF7a) acts as an immune evasin by downregulating HLA class I molecules
82 from the surface of infected cells. By abrogating HLA class I antigen presentation, ORF7a may
83 facilitate evasion of cytotoxic T cell responses in infected individuals.

84 **Material and Methods**

85 **Cell lines and viruses**

86 HEK-293T and HK-1 cells were maintained in Roswell Park Memorial Institute medium (RPMI
87 1640; Life Technologies) supplemented with 5% FCS (Sigma), 2 mM L-glutamine, 100 U/mL
88 penicillin, and 100 mg/mL streptomycin. The MeJuSo, Huh7 and A549-ACE2-TMPRSS2 cells were
89 maintained in Dulbecco's modified Eagle medium (DMEM; Life Technologies) supplemented with
90 5% FCS (Sigma), 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin.

91 SARS-CoV-2 strain NL/2020 was obtained from the European Virus Archive global (EVAg, Ref-SKU
92 010V-03903). A Δ ORF7a recombinant SARS-CoV-2 virus encoding the GFP gene at the ORF7a
93 locus [9] and the parental SARS-CoV-2 isolate harbouring an intact ORF7a gene were kindly
94 provided by Prof. Volker Thiel (Institute of Virology and Immunology, Bern, Switzerland). All
95 viruses were propagated and titrated on Vero E6 cells using the tissue culture infective dose 50
96 (TCID₅₀) endpoint dilution method. Propagation and experiments with infectious SARS-CoV-2
97 viruses were conducted in our BSL3 lab.

98

99 **Plasmids**

100 The plasmids of the SARS-CoV-2 cDNA library as cloned in the pLVX-EF1alpha-IRES-Puro
101 (Takara/Clontech) vector were a kind gift from Prof. Nevan Krogan (University of California San
102 Francisco, USA) [10]. The library lacked NSP3 and NSP16. Additionally, as the viral Spike gene was
103 provided in a different backbone vector, the cDNA was transferred to pLVX-EF1alpha-IRES-Puro
104 (Takara/Clontech) by classic restriction digest and ligation. Lentiviral cDNA plasmids were
105 transduced into HEK-293T cells and after antibiotic selection subjected to HLA class I surface level

106 quantification by flow cytometry. Cell lines expressing NSP1 and NSP14 did not survive
107 transduction and subsequent antibiotic selection and were, therefore, excluded from the analysis
108 For follow-up studies, we cloned a T2A-mAmetrine cassette in frame downstream of the PuroR
109 gene in the pLV-CMV-IRES-PuroR vector. This vector (pLV-CMV-IRES-PuroR-T2A-mAmetrine;
110 a.k.a. RP-1023) served as backbone vector for all subsequent cDNA variants. We cloned untagged
111 and C-terminally StrepII-tagged variants of SARS-CoV-2 ORF7a, SARS-CoV-2 ORF8, and SARS-CoV-
112 1 ORF7a Gibson cloning procedures in the RP-1023 vector. For SARS-CoV-1 ORF7a, overlapping
113 ± 90 nt ssDNA oligos (IDT Europe) were assembled by overlap extension PCR and cloned (with and
114 without a C-terminal Strep-II tag) in the RP-1023 vector. The sequences of the coding regions of
115 ORF7a and ORF8 (both non-tagged and StrepII-tagged) are presented in Table S1). Chimeric
116 ORF7a molecules, comprising of indicated sequences from both SARS-CoV-1 ORF7a and SARS-
117 CoV-2 ORF7a were constructed by PCR amplification using primers that incorporated the desired
118 nucleotide substitutions (primers used are presented in Table S2). All vectors were sequence-
119 verified by Sanger sequencing.

120 ACE2-GFP and TMPRSS2-HA for the A549-ACE2-TMPRSS2 cells were cloned from vectors kindly
121 provided by Dr. Wentao Li and Dr. Berend Jan Bosch (Utrecht University, Utrecht, The
122 Netherlands) into lentiviral vectors, where they were expressed from a hEF1A promoter. The
123 lentiviral plasmid also contains a PGK promoter driving expression of a blasticidin resistance gene
124 and a BlastR-T2A-eGFP cassette for the ACE2-GFP and TMPRSS2-HA expression vector
125 respectively.

126
127

128 **Lentivirus transductions**

129 For the pLVX-EF1alpha-IRES-Puro vector system, lentiviral particles were prepared using the
130 Lenti-X™ Packaging system (Takara Bio). For the pLV-CMV-IRES-PuroR-T2A-mAmetrine vectors,
131 lentiviruses were produced using standard lentiviral production protocols with third-generation
132 packaging vectors. Upon lentivirus production, viral supernatants were centrifuged at 3000rpm
133 and stored at -80°C until further use. In general, ~25k target cells were infected with ~100 µl
134 lentivirus supernatants in 24 well plates.

135

136 **SARS-CoV-2 infections**

137 SARS-CoV-2 viruses (see section ‘cell lines and viruses’) propagated in Vero E6 cells were used to
138 infect Vero E6 or A549-ACE2-TMPRSS2 cells. Briefly, cells were plated in a 24 well plate the day
139 before infection, and subsequently mock infected or infected at a multiplicity of infection (MOI)
140 of 0.01 (for Vero E6 cells) or 0.5 (for A549-ACE2-TMPRSS2 cells) in DMEM supplemented with 2%
141 FCS. After a 1-hour incubation, the inoculum was removed and cells were maintained in
142 complete medium for one or two days. Subsequently, cells were detached by TrypLE™ (Thermo)
143 and fixed in 4% PFA prior to surface MHC-I and Spike antibody stainings. Cells were subjected to
144 flow cytometry (BD FACS Canto II) and the data was analyzed with FlowJo (BD Biosciences)
145 software.

146

147 **Intracellular staining**

148 Cell lines used for intracellular HLA-I stainings were harvested using trypsin (Gibco) and pelleted
149 by centrifugation. The supernatant was removed, cells were washed in icecold PBA (PBS + 0.5%

150 BSA + 0.02% NaAzide) and pelleted again. Cells were then fixed in icecold 3.7% PFA in PBS for 10
151 min. After a washing step with icecold PBS, cells were incubated in icecold PBS + 0.5% saponin +
152 2% FCS for 10 min. Cells were then incubated for 30 min at 4°C with the conjugated antibody in
153 icecold PBS + 0.5% saponin + 2% FCS and after two subsequent washing steps fixed with icecold
154 3.7% PFA in PBA and subjected to flow cytometry analysis (BD FACS Canto II). The antibody used
155 was: PE-conjugated W6/32 (Serotec MCA81PE, 1:5) [11].

156

157 **Surface staining**

158 Cell lines used for surface stainings were harvested using trypsin (Gibco) and pelleted by
159 centrifugation. The supernatant was removed, cells were washed in icecold PBA (PBS + 0.5% BSA
160 + 0.02% NaAzide) and pelleted again. Cells were then incubated for 30 min at 4°C with the
161 directly-conjugated antibody and after two subsequent washing steps fixed with icecold 3.7%
162 PFA in PBA and subjected to flow cytometry analysis (BD FACS Canto II). The antibodies used
163 were: PE-conjugated W6/32 (Serotec MCA81PE, 1:10) [11], anti-CD9-FITC (BD Pharmingen
164 555371, 1:40), anti-CD46-FITC (BD Pharmingen 555949, 1:20), anti-CD49b-PE (BD Pharmingen
165 555669, 1:20), anti-CD58-PE (BD Pharmingen 555921, 1:30), anti-CDw119-PE (BD Pharmingen
166 558934, 1:20).

167 The primary antibody used for Spike staining was human anti-SARS-CoV-2 Spike (1:682, REGN
168 #10987), which was kindly provided by Wentao Li and Berend Jan Bosch (Utrecht University,
169 Utrecht, The Netherlands). The goat anti-human IgM+ IgG (H+L) (1:160, Jackson #109-116-127)
170 antibody was used as secondary antibody

171

172 **Inhibition of proteasome and p97**

173 For proteasome inhibition, we employed 20 μ M MG132 (Sigma-Aldrich, Zwijndrecht, NL, C2211-
174 5MG) and for p97 inhibition 4 μ M CB-5083 (HY-12861; MCE) for 4h each.

175

176 **Immunoblotting and immunoprecipitations**

177 Following cell lysis in Triton (1% Triton X-100, 50 mM Tris HCl [pH 7.5], 150 mM NaCl) lysis buffer
178 supplemented with 10 μ M Leupeptin (Roche), and 1 mM AEBSF, proteins were denatured in
179 reducing sample buffer. Samples were incubated at 95°C for 5 min prior to loading. For SDS-PAGE,
180 4-12% Bolt Bis-Tris Plus SDS gels (Thermo Scientific) were used. The proteins were transferred to
181 Trans-Blot Turbo PVDF membranes (BIO-RAD) using a Trans-Blot Turbo transfer system (BIO-RAD)
182 for 10 minutes at 25V. Membranes were incubated for 1h at room temperature (RT) in PBS
183 containing 0.05% Tween 20 (PBST) and 4% milk powder (Campina). Primary antibodies were
184 diluted in PBST supplemented with 1% milk powder and incubated overnight at 4°C. Membranes
185 were washed three times for 5 min with PBST at RT. HRP-labelled secondary antibodies were
186 diluted in PBST supplemented with 1% milk powder and used to incubate the membranes in the
187 dark for two hours at 4°C, or one hour at RT. Membranes were again washed three times for 5
188 min with PBST at RT before detection. Pierce ECL Western Blotting Substrate (Thermo Scientific)
189 was added to the membranes for detection of chemiluminescence, followed by image acquisition
190 (Image Quant LAS 4000). The primary antibodies used for immunoblotting were: HC10,
191 monoclonal mouse anti-SARS-CoV-2 ORF7a (Genetex, 632602, 1:1000), polyclonal rabbit anti-
192 SARS-CoV-2 ORF8a (Genetex, 135591, 1:1000), monoclonal transferrin receptor antibody (H68.4,
193 Invitrogen, 1:1000) and monoclonal StreptII (C23.21, purified in our lab). Secondary antibodies

194 used were goat anti-mouse IgG-HRP (115-035-174, Jackson ImmunoResearch Europe Ltd,
195 1:10000) and mouse anti-rabbit IgG-HRP (211-032-171, Jackson ImmunoResearch Europe Ltd,
196 1:10000). For empty vector and ORF7a immunoprecipitation 30-40 million cells per condition
197 were taken up in Triton (1% Triton X-100, 50 mM Tris HCl [pH 7.5], 150 mM NaCl) lysis buffer
198 supplemented with 10 μ M Leupeptin (Roche), and 1 mM AEBSF at 7-10 days post transduction.
199 For StrepII IP 25 μ l Streptactin Sepharose[®] High Performance beads (GE Healthcare, GE28-9355-
200 99) and for HLA-I IP 25 μ l Protein G Sepharose[®] 4 Fast Flow (GE Healthcare, GE17-0618-01) were
201 employed with the HC10 antibody for HLA-IP overnight at 4°C. Glycosylation status was detected
202 by treatment with Endo H_f (P0703L, NEB) and N-Glycosidase F (11365177001, Roche) for 1h at
203 37°C prior to loading for SDS-PAGE.

204

205 **Immunofluorescence**

206 Cells were fixed in 4% paraformaldehyde and 4% sucrose in PBS for 10 min with prewarmed
207 fixative. After fixation, cells were washed in PBS, permeabilized in 0.5% Triton X-100 in PBS for
208 10 min and blocked in 3% BSA in PBS for 15 min, incubated with primary antibodies for 16 h at
209 4°C, washed three times with 0.1% Triton X-100 in PBS (PBST) for 10 min, and incubated with
210 secondary antibodies together with DAPI for 2h at room temperature. Coverslips were then
211 washed 2x with PBST and 1x with PBS each for 10 min, rinsed with 96% ethanol, dried, and
212 mounted using antifade (ProLong Diamond; Molecular Probes). The following antibodies were
213 used: mouse anti-SARS-CoV-2 ORF7a (Genetex, 632602, 1:1000) and mouse anti-W6/32 (own
214 production from hybridoma, 1:1000). Secondary antibodies used were goat anti-mouse IgG2a
215 cross-adsorbed secondary antibody, Alexa Fluor 594 (Thermo Fisher, A-21135, 1:600) and goat

216 anti-mouse IgG1 cross-adsorbed secondary antibody, Alexa Fluor 647 (Thermo Fisher, A-21240,
217 1:600), together with DAPI (Sigma-Aldrich, 1:1000).

218

219 **Microscopy**

220 Images were acquired using a Zeiss LSM880 Fast Airyscan microscope with 405 nm, 561 nm, 633
221 nm and argon multiline lasers, internal Zeiss spectral 3 PMT detector and spectroscopic detection
222 using a Plan-Apochromat 63x/1.2 glycerol objective.

223

224 **Protein sequence alignments**

225 Protein sequence alignments were made using MUSCLE in the Snappene software package (GSL
226 Biotech). ORF7a from the following virus isolates were aligned: SARS-CoV-2 (QZX66581.1), SARS-
227 CoV-1 (SARS coronavirus Tor2; YP_009825057.1), Pangolin coronavirus (QIG55950.1), Bat
228 coronavirus BM48-31 (ADK66846.1), Bat SARS coronavirus HKU3-2 (AAZ41334.1), Bat
229 Betacoronavirus sp. RmYN07 (QWN56217.1), Bat Betacoronavirus sp. RpYN06 (QWN56257.1),
230 and Bat Betacoronavirus sp. RsYN03 (QWN56237.1).

231 **Results**

232 **MHC class I surface expression is downregulated upon SARS-CoV-2 Infection**

233 The MHC class I antigen presentation pathway is a common target for viruses to evade the host's
234 immune system. We asked whether also SARS-CoV-2 can interfere with this cellular defense
235 mechanism. We infected Vero E6 cells with the SARS-CoV-2 NL/2020 strain at an MOI of 0.01 and
236 assessed MHC class I surface levels by flow cytometry at 1 and 2 dpi. Indeed, MHC class I surface
237 levels were downregulated in Spike-expressing cells as compared to uninfected cells present in
238 the same culture (Fig 1A) at 2 dpi, but not at 1 dpi. We next measured the effect of SARS-CoV-2
239 infection in human cells, for which we transduced A549 cells with ACE2 and TMPRSS2 and
240 subsequently challenged these with SARS-CoV-2 NL/2020 at an MOI of 0.5. Also here, HLA class I
241 surface levels were reduced in Spike-expressing cells at 2 dpi (Fig 1B). Our results show that SARS-
242 CoV-2 infection induces downregulation of MHC class I surface levels in both a monkey and a
243 human cell line.

244

245 **SARS-CoV-2 ORF7a downregulates surface HLA-I**

246 The SARS-CoV-2 genome consists of 14 open-reading frames (ORFs), which encode for 31 viral
247 proteins [12]. To assess which viral gene product causes surface HLA class I downregulation, we
248 transduced a library of StrepII-tagged SARS-CoV-2 cDNAs in 293T cells and monitored HLA-I
249 surface levels by flow cytometry (Fig 2A). Of all viral cDNAs, only ORF7a showed a significant
250 downregulation of surface HLA-I levels of $\pm 55\%$ as compared to wt control cells (Fig 2B).
251 Unexpectedly, ORF8, which was previously identified to downregulate HLA class I levels [13], did
252 not impact HLA class I surface levels (Fig 2B).

253 To validate our finding, we subcloned the ORF7a cDNA in a different lentiviral vector. Also here,
254 ORF7a constructs potently downregulated HLA class I from the cell surface, whereas the ORF8
255 cDNA did not (Fig 2C). Both untagged and StrepII-tagged ORF7a induced potent downregulation
256 of surface HLA class I (Fig 2C), whereas neither untagged nor StrepII-tagged ORF8 reduced surface
257 HLA class I levels (Fig 2C and data not shown). The lack of HLA-I downregulation by ORF8 could
258 potentially be explained by a relatively low protein expression of ORF8 (Fig 2D), which was
259 apparent by Western blotting for the StrepII-tag located on the C-terminus of the protein. When
260 we followed HLA-I surface expression in ORF7a-transduced cells in time, we observed that the
261 HLA-I downregulation was transient and variable, and the phenotype was eventually lost after
262 approximately two weeks (data not shown). Our results show that ORF7a, but not ORF8,
263 downregulates HLA class I protein levels from the cell surface.

264

265 **ORF7a downregulates surface HLA-I in multiple cell lines and is specific to HLA class I**

266 SARS-CoV-2 ORF7a induced surface downregulation of HLA-I expression. To assess whether
267 ORF7a specifically downregulates HLA-I from the cell surface or rather impacts expression of
268 proteins that migrate through the secretory pathway, we monitored the surface expression of
269 multiple cell surface antigens in ORF7a-transduced 293T cells and compared this to the levels of
270 these antigens in cells transduced with the other SARS-CoV-2 cDNAs (Fig 3A). Besides HLA class I,
271 ORF7a did not impact the expression of CD9, CD46, CD49b, CD58 and CDw119 from 293T cells
272 (Fig 3A and 3B). This implies that ORF7a does not cause a general defect in the secretory pathway
273 that could explain for the loss of HLA-I from the cell surface, but rather that ORF7a specifically
274 induces HLA-I surface downregulation.

275 Next, we set out to confirm whether ORF7a also regulates HLA-I in additional cell lines. For this
276 we transduced ORF7a in the cutaneous melanoma cell line MelJuSo, the nasopharyngeal
277 carcinoma cell line HK-1 and the adult hepatocellular carcinoma cell line Huh7 (Fig. 3C). As
278 expected, all these ORF7a expressing cell lines displayed reduced HLA-I surface expression levels,
279 although the magnitude of downregulation varied between the cell lines.

280 We conclude that SARS-CoV-2 ORF7a specifically downregulates HLA-I from the surface of
281 multiple human cell lines

282

283 **The ORF7a signal peptide sequence and transmembrane domain are essential for HLA-I surface** 284 **downregulation**

285 SARS-CoV-2 ORF7a is an 121 aa ER-resident protein consisting of a 15 aa signal peptide sequence,
286 followed by an 81 aa luminal domain, a 20 aa transmembrane (TM) domain and a 5 aa tail [12].

287 To pinpoint important domains of ORF7a that are crucial for HLA-I downregulation, we generated
288 different SARS-CoV-2 mutants (Fig. 4A) and assessed whether HLA-I surface regulation was
289 impaired.

290 We generated three mutants, replacing the ORF7a signal peptide sequence with the signal
291 peptide sequence of human CD8A (CD8S-ORF7a), mutating the extreme C-terminal endoplasmic
292 reticulum (ER) retrieval motif KRKTE [14] to KAAAA (ORF7a Tail-mut), and deleting the
293 transmembrane and cytoplasmic tail completely (ORF7a Δ TM/ Δ tail, Fig. 4A). The different ORF7a
294 variants were expressed in 293T cells (Fig 4B) and cell-surface expression of HLA-I was assessed
295 by flow cytometry at 6 dpi (Fig. 4C). As seen previously, ORF7a expression induced potent surface
296 HLA-I downregulation. Similar downregulation was observed upon introduction of the ORF7a tail-

297 mut variant in which the ER retrieval motif was mutated. On the contrary, both the CD8S-ORF7a
298 and the ORF7a Δ TM/ Δ tail mutant lost the ability to downregulate HLA-I surface expression. Our
299 results suggest that presence of the ORF7a signal peptide sequence and transmembrane domain
300 are crucial for HLA-I downregulation, whereas the ER-retrieval motif is dispensable for this
301 activity.

302

303 **A single amino acid substitution of SARS-CoV-1 ORF7a confers the ability to downregulate**
304 **surface HLA-I expression**

305 SARS-CoV-2 ORF7a shares high sequence homology with SARS-CoV-1 ORF7a (multiple sequence
306 alignment likelihood of 0,83) [15]. However, introduction of the SARS-CoV-1 ORF7a protein from
307 the 2002 outbreak in 293T cells did not result in HLA-I surface downregulation (Fig 5C, upper right
308 histogram). Therefore, HLA-I regulation appeared to be acquired by SARS-CoV-2 ORF7a upon
309 evolution of the SARS-CoV-1 ORF7a gene. Protein-sequence alignment of both ORF7a proteins
310 indicated that the sequence differences were predominantly located in three distinct 'regions' in
311 the protein: in the signal sequence, a small area in the luminal domain, and the stalk-TM region
312 (Fig. 5A). We reasoned that individual or multiple of these amino acid differences could be
313 responsible for the gain-of-function phenotype observed in SARS-CoV-2 ORF7a. To study this, we
314 replaced the three regions harbouring amino acid substitution of SARS-CoV-1 ORF7a with the
315 corresponding sequence of SARS-CoV-2 ORF7a (Fig. 5B) and assessed whether the chimeric SARS-
316 CoV-1 ORF7a proteins gained the ability to downregulate surface HLA-I expression. Indeed,
317 whereas the wt SARS-CoV-1 ORF7a and two of the chimeric proteins (I and III) did not
318 downregulate HLA-I, transfer of the luminal 'region II' from SARS-CoV-2 ORF7a to SARS-CoV-1

319 ORF7a resulted in potent downregulation of HLA-I from the cell surface (Fig. 5C). The transferred
320 region II of SARS-CoV-2 only has 6 aa differences as compared to the same region of SARS-CoV-1
321 ORF7a. To identify which aa changes were responsible for the gain-of-function phenotype, we
322 generated two chimeric mutants in which three amino acid changes were introduced in the SARS-
323 CoV-1 ORF7a sequence. Whereas one of these chimeric ORF7a molecules (T71V/R72K/T74V) was
324 not able to downregulate surface HLA-I levels (Fig. 5E, second overlay), introduction of the
325 T59F/H62Q/A68P chimeric ORF7a molecule in 293T cells resulted in strong HLA-I surface
326 downregulation (Fig. 5E). We next introduced all possible double and single aa changes from
327 these three amino acids into the SARS-CoV-1 ORF7a molecule and noticed that those SARS-CoV-
328 1 mutants that carried the T59F substitution gained the ability to downregulate HLA-I surface
329 levels (Fig. 5E). Also, the H62Q substitution induced minor HLA-I surface downregulation,
330 whereas the A68P substitution did not (Fig. 5E, right two overlays). We conclude that a single
331 amino acid substitution in SARS-CoV-1 ORF7a (T59F) caused the gain-of-function phenotype in
332 which surface HLA class I downregulation was acquired.

333 To assess whether the phenylalanine at position 59 in the SARS-CoV-2 ORF7a is also present in
334 other sarbecovirus isolates, we performed a protein-sequence alignment of multiple ORF7a
335 sequences obtained from the NCBI genome database (Fig. 5F). Indeed, we could readily identify
336 sarbecovirus isolates of pangolin and bat origin carrying this specific amino acid. It is conceivable
337 that these coronaviruses can also regulate surface MHC class I expression upon infection of cells
338 in their host, although we have not addressed this. It was apparent that position 59 of ORF7a has
339 considerate variability among virus isolates (Fig. 5F).

340 SARS-CoV-1 ORF7a has been shown to induce apoptosis in infected target cells [16-18]. Indeed,
341 293T cells transduced with SARS-CoV-1 ORF7a were quickly lost from the population of cells
342 within \pm one week after transduction, whereas SARS-CoV-2 ORF7a-transduced cells were not
343 (data not shown). Therefore, the gain-of-function in HLA-I downregulation of SARS-CoV-2 ORF7a
344 is accompanied by a loss-of-function in its ability to induce apoptosis. All chimeric SARS-CoV-1
345 ORF7a mutants we constructed induced apoptosis (data not shown), suggesting that the amino
346 acids substitution studied here are not essential for SARS-CoV-1 ORF7a-mediated apoptosis
347 induction.

348

349 **SARS-CoV-2 ORF7a induces intracellular HLA-I accumulation predominantly located in the ER**

350 To assess whether ORF7a induces surface HLA class I downregulation by protein degradation, we
351 assessed whether the total pool (both intracellular and surface expression) of HLA-I is depleted
352 upon ORF7a expression in 293T cells. Unexpectedly, intracellular levels of HLA class I were
353 potently upregulated in ORF7a-expressing 293T cells at 7 dpi, whereas HLA class I surface
354 expression was downregulated (Fig. 6A) as observed previously. Western blot analysis confirmed
355 that HLA-class I levels were upregulated in ORF7a-expressing cells as compared to EV controls
356 (Fig 6B). Also, intracellular accumulation of HLA-I persisted in ORF7a expressing cells, even at late
357 timepoints (21 dpi) when surface downregulation was already lost (data not shown).

358 HLA class I HCs carry an N-glycan in their luminal/extracellular domain. Endoglycosidase H
359 (EndoH)-treatment of lysates can provide information on the composition of the N-linked glycans
360 of HLA-I HCs and, hence, their location in the cell. EndoH can only cleave immature N-linked
361 glycans present on ER-resident glycoproteins, but not mature glycans present on proteins that

362 have migrated to the Golgi and beyond. To assess where HLA-I molecules accumulate in ORF7a-
363 transduced 293T cells, we incubated cell lysates with either EndoH or N-glycosidase. In control
364 293T cells, roughly half of the HLA-I molecules were ER-resident, as they were sensitive to EndoH-
365 cleavage (Fig 6C, lane 2). ORF7a-expression induced upregulation of HLA class I (Fig 6C, lane 4),
366 which was almost exclusively localized to the ER, as the products were sensitive to EndoH-activity
367 resulting in deglycosylation of the majority of upregulated HLA-molecules (Fig 6C, compare lane
368 4 with lane 5). Treatment of samples with peptide N-glycanase-F (GlycF), which cleaves all glycans
369 regardless of their maturation status, resulted in full cleavage of the N-glycan and provided a
370 marker to visualize the mobility of deglycosylated HLA-I HCs (Figure 6C, Lane 6).

371 In agreement with the EndoH-treatment experiments, immunofluorescent imaging of MeJuSo
372 cells transduced with ORF7a indicated that HLA-I accumulated in transduced cells in perinuclear
373 compartments, including the ER and potentially the ER-Golgi intermediate compartment (ERGIC).
374 Additionally, ORF7a-positive vesicles associated with HLA-I-positive structures. Our results
375 suggest that ORF7a induces intracellular accumulation of HLA-I in the ER.

376

377 **ORF7a-mediated surface HLA-I downregulation is abrogated upon proteasome- and p97-**
378 **inhibition, whereas intracellular HLA levels are unaffected**

379 HLA class I downregulation by ER-localized viral inhibitors can be mediated by ER-associated
380 protein degradation (ERAD). Dislocation of proteins from the ER back to the cytosol for
381 proteasomal degradation is a hallmark in ERAD and p97, a cytosolic AAA-ATPase that is essential
382 for ERAD, provides the driving force for this process. We next assessed whether the proteasome
383 or p97 are involved in ORF7a-mediated HLA-I surface downregulation. For this, we treated

384 control and ORF7a-transduced 293T cells with either the MG132 proteasome inhibitor or the CB-
385 5083 p97 inhibitor (p97i) for four hours prior assessment of surface and intracellular levels of
386 HLA class I (Fig. 7). As expected, in ORF7a-expressing cells and DMSO-treated ORF7a-expressing
387 cells, we observed downregulation of surface HLA-I, accompanied by upregulation of intracellular
388 HLA class I levels. Treatment with either MG132 or p97 inhibitor, however, abrogated ORF7a-
389 mediated HLA class I surface downregulation without impacting intracellular HLA-I protein levels.
390 Control cells transduced with the empty vector (EV) did not show regulation of intracellular nor
391 surface HLA-I in MG132 and p97-inhibitor treated cells. Our results suggest that ORF7a-mediated
392 HLA class I surface downregulation is dependent on p97 activity and the cellular proteasome
393 system, possibly by engaging the cellular ERAD machinery.

394

395 **ORF7a associates with HLA class I molecules**

396 ORF7a regulates HLA class I surface levels and co-localizes to the ER. We next asked whether
397 ORF7a directly associates with HLA-I. We transduced 293T cells with StrepII-tagged ORF7a or
398 empty vector and immunoprecipitated StrepII-tagged proteins from the lysate by means of
399 Streptactin beads. Subsequent immunoblotting for ORF7a showed a strong enrichment for the
400 protein (Fig 8, middle panel, lane 4), and co-precipitation of HLA class I was apparent (Fig 8, lower
401 panel, lane 4). This co-precipitation was not observed in control cells transduced with the EV.
402 Additionally, as control, the transferrin receptor (TfR) did not co-precipitate upon ORF7a pull
403 down.
404 Also vice versa, ORF7a was specifically co-precipitated upon HLA class I pull down using the HC10
405 anti-HLA-I antibody. Thus, ORF7a is associated with HLA class I molecules in the cell, potentially

406 via a direct interaction between the proteins. It is suggestive that the luminal domain of ORF7a
407 interacts with the luminal domain of HLA-I HCs, as both are situated in the ER and mutations in
408 the ORF7a luminal domain region (Fig 5) impact activity.

409
410 In summary, we show that ORF7a from SARS-CoV-2 downregulates HLA class I molecules from
411 the surface of human cells. ORF7a interacts with HLA class I molecules, likely in the ER, resulting
412 in increased intracellular HLA class I levels, yet abrogating HLA class I surface expression. ORF7a
413 is dependent on its signal peptide sequence and transmembrane domain to mediate HLA class I
414 surface downregulation, whereas the conserved ER-retrieval motif in its cytoplasmic tail is
415 dispensable for this activity. Additionally, we show that ORF7a from SARS-CoV-1 does not direct
416 surface HLA class I downregulation, but that a single amino acid substitution to the corresponding
417 SARS-CoV-2 ORF7a sequence (T59F) yields a gain-of-function phenotype in which surface HLA
418 class I molecules are downregulated. Importantly, HLA class I surface expression is impaired in
419 SARS-CoV-2 infection models, which could partially be mediated by ORF7a activity. We
420 hypothesize that SARS-CoV-2 can evade cytotoxic T lymphocytes immune responses towards
421 infected cells via ORF7a-mediated interference with antigen presentation thereby evading
422 immune surveillance. The ability of SARS-CoV-2 to interfere with its hosts adaptive immune
423 system may contribute to the pathology of COVID-19.

424

425

426 **Discussion**

427 Viral infections induce innate and adaptive immune responses in their host that inhibit virus
428 replication and spread. As countermeasure, many viruses have evolved strategies to interfere
429 with the antiviral immune response [19-21]. Here, we identified that ORF7a from SARS-CoV-2 can
430 thwart the antigen presentation pathway by downregulating surface HLA class I surface
431 expression, thereby potentially evading cytotoxic T cell responses targeted to virus-infected cells.
432 HLA class I genes are highly polymorphic and may contribute to susceptibility and severity of
433 COVID-19 [22-27]. Based on *in silico* analysis of HLA class I binding affinity for SARS-CoV-2
434 peptides, Nguyen *et al.* suggested that patients carrying the HLA-B*4601 genotype are more
435 vulnerable to COVID-19, as this variant has a relatively low binding affinity for SARS-CoV-2
436 peptides [22]. This same genotype was associated with severe disease caused by SARS-CoV-1 in
437 another study [28]. Furthermore, individuals with a HLA-A*01:01 and HLA-C*04:01 genotype
438 have an increased risk to develop severe clinical course of COVID-19 [24,25]. Kreutmair *et al.*
439 employed NGS-based HLA class I typing in a patient cohort and integrated the data with single-
440 cell immune profiling analysis to severe COVID-19-associated immune features [27]. They
441 concluded that weak HLA class I binding, and thus impaired virus recognition, could partially drive
442 the immunopathology of COVID-19. These results support earlier studies where patients with
443 mild disease presented HLA class molecules with a higher theoretical capacity for binding SARS-
444 CoV-2 peptides as compared to moderate and severe COVID-19 groups [29]. These studies
445 illustrate that antigen presentation in general is important to limit SARS-CoV-2 infection. In line
446 with this, SARS-CoV-2 can subvert CD8⁺ T cell surveillance through point mutations in HLA-I-
447 restricted viral epitopes [30]. Hence, interference in antigen presentation by SARS-CoV-2 could

448 be advantageous for the virus to escape from its host's immune system. Besides by selecting for
449 mutations in HLA-I viral epitopes, evasion can be mediated by viral gene-products that directly
450 target antigen presentation, such as ORF7a.

451 SARS-CoV-2 ORF7a is a transmembrane protein which localizes to the Golgi/ERGIC [31-34]. ORF7a
452 has a five amino acid cytosolic tail containing a dilysine (KRKTE) endoplasmic reticulum (ER)
453 retrieval signal (ERRS). This motif is common for Golgi residing proteins and mediates protein
454 trafficking to the ER-Golgi intermediate compartment (ERGIC) [14,33,35,36]. Mutation of the
455 cytosolic tail of ORF7a (from KRKTE to KAAAA) did not abrogate HLA class I downregulation from
456 the cell surface, suggesting that the motif is not required for this activity. However, studies on
457 SARS-CoV-1 ORF7a suggest that additional residues in the transmembrane domain impact
458 protein trafficking [33]. Indeed, by deleting the entire transmembrane domain and the cytosolic
459 tail, ORF7a-mediated HLA class I surface downregulation was fully impaired, likely caused by
460 disturbed localization of the protein and loss of its ability to reside at the ER/Golgi membrane. In
461 line with this, a SARS-CoV-2 isolate with an 115 nt deletion in the ORF7a gene encompassing the
462 transmembrane region and ERRS motif, displayed ORF7a expression in the cytosol instead of the
463 perinuclear region [32]. Both SARS-CoV-1 ORF7a and SARS-CoV-2 ORF7a carry a 15 amino acid
464 signal peptide at their N-terminus, which is cleaved from the native ORF7a upon entry into the
465 ER [33]. Unexpectedly, however, replacement of the SARS-CoV-2 ORF7a signal peptide sequence
466 with that of the CD8A protein abrogated the ability to downregulate HLA class I from the cell
467 surface. This suggests that the ORF7a signal peptide, besides guiding the protein into the
468 secretory pathway during translation, is involved in the ORF7a-mediated downregulation of
469 surface HLA-I.

470 BST-2 (tetherin) restricts the release of viruses from cells and SARS-CoV-1 ORF7a has been shown
471 to inhibit BST-2 by blocking its glycosylation [37]. The same has been shown for SARS-CoV-2
472 ORF7a [31]. A preprint showed that the loss of tetherin increased virus titers and spread of SARS-
473 CoV-2, but that this effect was mediated by the viral spike protein, whereas SARS-CoV-2 ORF7a
474 induced Golgi fragmentation [38]. The Golgi apparatus is crucial for HLA class I transport to the
475 cell surface and it has been shown for various viruses, including SARS-CoV-1 and SARS-CoV-2, that
476 infection can result in Golgi fragmentation [38-42]. Infection with Orf virus for example results in
477 Golgi fragmentation and subsequent impairment of intracellular MHC class I transport [39].
478 ORF7a-mediated Golgi fragmentation may contribute to decreased HLA-I surface levels through
479 impaired transport of heavy chains through the secretory pathway.

480 We show that ORF7a specifically downregulates HLA-I from the cell surface, as other cell-surface
481 receptors that migrate through the secretory pathway are unaffected by the viral gene product.
482 Also, our data suggests that ORF7a is localized to perinuclear vesicles, potentially associated with
483 the ER; that the protein associates with HLA class I heavy chains; and that ORF7a expression
484 results in accumulation of HLA-I heavy chains in the ER. These data suggest that ORF7a specifically
485 binds to HLA-I HCs in the ER, either retaining HLA class I HC molecules, or interfering with their
486 migration to the Golgi network for subsequent presentation to the cell surface. It is probable that
487 a region in the ER luminal domain of ORF7a mediates the HLA-I HC binding, as we showed that
488 SARS-CoV-1 ORF7a mutations in the luminal domain resulted in a gain-of-function of HLA-I
489 downregulation. Upon inhibition of the proteasome or p97, ORF7a-mediated surface HLA-I
490 downregulation was impaired. It is conceivable that blockage of HLA class I degradation via the
491 proteasome in the face of ORF7a expression, results in enhanced HC accumulation in the ER

492 thereby overloading ORF7a's ability to engage HLA-I molecules, ultimately resulting in re-
493 appearance of HLA-I expression on the cell surface. Alternatively, ORF7a may also engage the
494 ERAD machinery directly to induce surface HLA-I downregulation, as has been observed for viral
495 gene products of other viruses [43]. For example, HCMV US2 and US11 encode for ER
496 transmembrane proteins that mediate HLA-I degradation by engaging the ERAD machinery
497 [44,45]. US2 and US11 bind to HLA-I HCs in the ER to promote their downregulation in concert
498 with multiple host factors such as the E3 ubiquitin ligase TRC8 [46], the AAA-ATPase p97 [47] for
499 US2 and the E3 ubiquitin ligase TMEM129 [48,49], p97, Ufd1 and Npl4 [50] for US11. ERAD and
500 p97 are responsible for the dislocation of proteins from the ER back to the cytosol for subsequent
501 proteasomal degradation and could be involved in the ORF7a-driven surface downregulation of
502 HLA-I as well. However, whereas US2 and US11 induce degradation of HLA-I HCs from the cell,
503 ORF7a-expressing 293T and MeIJuSo cells show increased intracellular HLA-I levels in conjunction
504 with reduced cell-surface levels. Hence, ERAD-mediated class I degradation alone does not
505 explain the observed phenotype. It is possible that ORF7a-mediated HLA-I surface
506 downregulation and ORF7a-mediated intracellular accumulation are the result of two separate
507 mechanisms. Indeed, our preliminary observations showed that, in Huh7 cells, ORF7a-mediated
508 surface HLA-I downregulation occurs in the absence of intracellular HLA-I accumulation (data not
509 shown), suggesting that the processes may be decoupled and are cell-type specific. The molecular
510 mechanism of HLA-I surface downregulation by SARS-CoV-2 ORF7a remains unknown and awaits
511 further clarification.

512 Besides ORF7a, multiple studies have identified SARS-CoV-2 gene products to interfere with
513 MHC-I expression. A recent preprint showed that several SARS-CoV-2 gene products have the

514 capacity to downregulate MHC-I molecules, including the viral E, M, ORF7a, ORF7b, and ORF8
515 proteins [51]. In this study, no additional experiments were performed to address the nature of
516 MHC-I regulation. Zhang *et al.* reported that SARS-CoV-2 ORF8 selectively targets HLA class I
517 molecules for lysosomal degradation in an autophagy-dependent manner [13]. Contrary to our
518 findings, the authors reported that ORF7a did not result in surface HLA class I downregulation in
519 HEK-293T cells. Another recent study identified SARS-CoV-2 ORF6 to suppress the HLA-I
520 transactivator NLRC5, thereby inhibiting the induction of HLA-I gene expression, without
521 impacting steady-state HLA-I expression levels [52]. Also here, the authors did not observe an
522 effect of ORF8 on HLA-I expression, whereas ORF7a was not included in their experiments. In our
523 study, we do not find experimental evidence for a role of either ORF6 nor ORF8 on steady-state
524 HLA class I surface expression levels, which agrees with Yoo *et al.* [52], but not with Zhang *et al.*
525 [13]. It is not clear why the inhibitory effect of ORF8 on HLA class I expression was not observed
526 in our study; potentially, ORF8 activity can only be observed under specific experimental
527 conditions. In line with this reasoning, we observed a transient effect of SARS-CoV-2 ORF7a
528 mediated HLA-I downregulation (data not shown), and the potency of downregulation varied
529 between experiments. Therefore, ORF7a-mediated HLA-I regulation may be overlooked by
530 others. Despite these different findings, it is remarkable that SARS-CoV-2 has evolved multiple
531 strategies to thwart with HLA class I antigen presentation. To assess the specific contribution of
532 ORF7a on HLA-I downregulation during infection, we used a recombinant SARS-CoV-2 strain in
533 which the ORF7a gene was substituted with the GFP gene [9]. This virus however, induced
534 equivalent HLA-I surface downregulation as compared to the parental ORF7a-encoding SARS-
535 CoV-2 strain in both Vero E6 and A549-ACE2-TMPRSS2 cells (Supplemental Fig.1). It is likely that

536 abrogation of the ORF7a-mediated HLA-I downregulation alone is not sufficient to contribute to
537 a detectable increase of surface HLA-I levels, as multiple viral gene products that target HLA-I are
538 still functionally expressed (ORF6, ORF8, E, M). If, and to what extent, each of these genes
539 contribute to the inhibition of cytotoxic T cell responses *in vivo* remains to be determined.

540 SARS-CoV-1 and SARS-CoV-2 ORF7a have a conserved immunoglobulin-fold carrying an integrin
541 binding site and the protein displays structural homology to ICAM-1 [53]. ICAM-1 is a ligand for
542 the T cell integrin receptor LFA-1 [54] and their engagement is important for T cell activation and
543 motility [55,56]. Various deletions have been reported in the ORF7a gene, some resulting in
544 ORF7a/7b or ORF7a/8 fusion products [32,57-59]. In these strains, amino acid E26 is maintained,
545 which is a position in the ORF7a Ig fold that harbours the integrin binding region for LFA-1 (and
546 Mac-1) [53]. Interestingly, both ORF7a and ORF8 carry an Ig-fold and share distant nucleotide
547 sequence similarity [60-64], suggesting that they are paralogs that could share similar immune
548 antagonistic functions. Neither ORF7a nor ORF8 are present in members of the gamma- or
549 deltacoronaviruses and, most surprisingly, not in MERS [60].

550 By replacing several amino acids of the luminal domain of SARS-CoV-1 ORF7a with that of the
551 corresponding SARS-CoV-2 ORF7a sequence, SARS-CoV-1 ORF7a gained the ability to
552 downregulate surface HLA-I expression levels. Intriguingly, only a single amino acid substitution
553 (T59F) was responsible for the gain-of-function phenotype. This suggests that the F59 position of
554 SARS-CoV-2 ORF7a is of key importance for ORF7a activity. Indeed, protein sequence alignment
555 of multiple sarbecovirus ORF7a sequences indicated that the 59 position has significant variation.
556 Where multiple sarbecoviruses ORF7a proteins carry a bulky hydrophobic phenylalanine (F) or
557 isoleucine (I) at this position, other sarbecoviruses have a small polar amino acid at this site (T:

558 Threonine, or S: Serine). Although we have not assessed whether ORF7a from additional
559 sarbecoviruses can also abrogate surface MHC class I expression, it is likely that this ability is
560 shared with other members of the family. It is striking that a single amino acid change in ORF7a
561 can direct such a fundamental change in phenotype.

562 In conclusion, our data shows that the SARS-CoV-2 accessory protein ORF7a directly associates
563 with HLA-I and inhibits HLA-I surface expression levels in human cells. By abrogating HLA class I
564 antigen presentation, ORF7a may facilitate the evasion of cytotoxic T cell responses thereby
565 acting pro-viral. Future therapeutical interventions by targeting ORF7a may lead to improved
566 clearance of SARS-CoV-2 infected cells thereby limiting infection and spread.

567

568 **Note added prior submission**

569 In the process of submitting this paper, two preprint were published in which SARS-CoV-2 ORF7a
570 was also identified to regulate HLA-I expression [65,66]. The data presented in these preprints
571 are largely in agreement with our findings.

572

573 **Acknowledgements**

574 We would like to thank the members of the Wiertz and Lebbink lab for conducive discussions.
575 This work was supported by grants from the European Commission under the Horizon2020
576 program H2020 MSCA-ITN GA 675278 EDGE to EJHJW and RJI Health~Holland (grant number
577 LSHM20058) to JMB, MN, and RJI; and Deutsche Forschungsgemeinschaft (DFG) grant GK1949/2
578 to ID. Further support came from the European Research Council (ERC Consolidator Grant 819219

579 to L.C.K.) and the Centre for Living Technologies, a part of the Alliance TU/e, WUR, UU, UMC
580 Utrecht (www.ewuu.nl).

581
582 **Author contributions**
583 SZ, HdB, PP, and RJL conceived and designed the experiments. HdB and PP performed initial
584 experiments to identify ORF7a as inhibitor of HLA-I expression. MvG and WN performed the
585 immunofluorescence experiments. SZ, HdB, and AE generated plasmids and reagents. YL and ID
586 contributed reagents. PP and MvG performed live SARS-CoV-2 experiments. AE performed the
587 proteasome/p97 inhibitor experiments, IBB performed all biochemical experiments. LdV assisted
588 with flow cytometry stainings. SZ performed all other experiments. LCK, JMB, MN, EJHJW, and
589 RJL provided support, reagents, and funding. SZ, HdB, and RJL wrote the paper with input from
590 all the other authors.

591
592 **References**

- 593 1. Cui J, Li F, Shi ZL: **Origin and evolution of pathogenic coronaviruses.** *Nat Rev Microbiol*
594 2019, **17**:181-192.
595 2. Fung TS, Liu DX: **Human Coronavirus: Host-Pathogen Interaction.** *Annu Rev Microbiol*
596 2019, **73**:529-557.
597 3. Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA: **The molecular**
598 **virology of coronaviruses.** *J Biol Chem* 2020, **295**:12910-12934.
599 4. Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL: **Coronavirus**
600 **RNA Proofreading: Molecular Basis and Therapeutic Targeting.** *Mol Cell* 2020,
601 **79**:710-727.
602 5. Harrison AG, Lin T, Wang P: **Mechanisms of SARS-CoV-2 Transmission and**
603 **Pathogenesis.** *Trends Immunol* 2020, **41**:1100-1115.
604 6. V'Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V: **Coronavirus biology and replication:**
605 **implications for SARS-CoV-2.** *Nat Rev Microbiol* 2020.
606 7. Golstein P, Griffiths GM: **An early history of T cell-mediated cytotoxicity.** *Nat Rev*
607 *Immunol* 2018, **18**:527-535.
608 8. Praest P, de Buhr H, Wiertz E: **A Flow Cytometry-Based Approach to Unravel Viral**
609 **Interference with the MHC Class I Antigen Processing and Presentation Pathway.**
610 *Methods Mol Biol* 2019, **1988**:187-198.

- 611 9. Thi Nhu Thao T, Labroussaa F, Ebert N, V'Kovski P, Stalder H, Portmann J, Kelly J, Steiner
612 S, Holwerda M, Kratzel A, et al.: **Rapid reconstruction of SARS-CoV-2 using a**
613 **synthetic genomics platform**. *Nature* 2020, **582**:561-565.
- 614 10. Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K,
615 Guo JZ, Batra J, et al.: **Comparative host-coronavirus protein interaction networks**
616 **reveal pan-viral disease mechanisms**. *Science* 2020, **370**.
- 617 11. van de Weijer ML, van Muijlwijk GH, Visser LJ, Costa AI, Wiertz EJ, Lebbink RJ: **The E3**
618 **Ubiquitin Ligase TMEM129 Is a Tri-Spanning Transmembrane Protein**. *Viruses*
619 2016, **8**.
- 620 12. Redondo N, Zaldivar-Lopez S, Garrido JJ, Montoya M: **SARS-CoV-2 Accessory Proteins**
621 **in Viral Pathogenesis: Knowns and Unknowns**. *Front Immunol* 2021, **12**:708264.
- 622 13. Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, Xia B, Ma X, Yang T, Yu F, et al.: **The**
623 **ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating**
624 **MHC-I**. *Proc Natl Acad Sci U S A* 2021, **118**.
- 625 14. Fielding BC, Tan YJ, Shuo S, Tan TH, Ooi EE, Lim SG, Hong W, Goh PY: **Characterization**
626 **of a unique group-specific protein (U122) of the severe acute respiratory**
627 **syndrome coronavirus**. *J Virol* 2004, **78**:7311-7318.
- 628 15. Holcomb D, Alexaki A, Hernandez N, Hunt R, Laurie K, Kames J, Hamasaki-Katagiri N,
629 Komar AA, DiCuccio M, Kimchi-Sarfaty C: **Gene variants of coagulation related**
630 **proteins that interact with SARS-CoV-2**. *PLoS Comput Biol* 2021, **17**:e1008805.
- 631 16. Tan YJ, Fielding BC, Goh PY, Shen S, Tan TH, Lim SG, Hong W: **Overexpression of 7a, a**
632 **protein specifically encoded by the severe acute respiratory syndrome**
633 **coronavirus, induces apoptosis via a caspase-dependent pathway**. *J Virol* 2004,
634 **78**:14043-14047.
- 635 17. Schaecher SR, Touchette E, Schriewer J, Buller RM, Pekosz A: **Severe acute respiratory**
636 **syndrome coronavirus gene 7 products contribute to virus-induced apoptosis**. *J*
637 *Virol* 2007, **81**:11054-11068.
- 638 18. Tan YX, Tan TH, Lee MJ, Tham PY, Gunalan V, Druce J, Birch C, Catton M, Fu NY, Yu VC,
639 et al.: **Induction of apoptosis by the severe acute respiratory syndrome**
640 **coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein**. *J*
641 *Virol* 2007, **81**:6346-6355.
- 642 19. Schuren AB, Costa AI, Wiertz EJ: **Recent advances in viral evasion of the MHC Class I**
643 **processing pathway**. *Curr Opin Immunol* 2016, **40**:43-50.
- 644 20. van de Weijer ML, Luteijn RD, Wiertz EJ: **Viral immune evasion: Lessons in MHC class I**
645 **antigen presentation**. *Semin Immunol* 2015, **27**:125-137.
- 646 21. Kasuga Y, Zhu B, Jang KJ, Yoo JS: **Innate immune sensing of coronavirus and viral**
647 **evasion strategies**. *Exp Mol Med* 2021, **53**:723-736.
- 648 22. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF: **Human**
649 **Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome**
650 **Coronavirus 2**. *J Virol* 2020, **94**.
- 651 23. Migliorini F, Torsiello E, Spiezia F, Oliva F, Tingart M, Maffulli N: **Association between**
652 **HLA genotypes and COVID-19 susceptibility, severity and progression: a**
653 **comprehensive review of the literature**. *Eur J Med Res* 2021, **26**:84.
- 654 24. Shkurnikov M, Nersisyan S, Jankevic T, Galatenko A, Gordeev I, Vechorko V, Tonevitsky A:
655 **Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19**.
656 *Front Immunol* 2021, **12**:641900.
- 657 25. Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Muller M, Patriki D, Quedenau
658 C, Kruger U, Ilinsky V, et al.: **Increased risk of severe clinical course of COVID-19 in**
659 **carriers of HLA-C*04:01**. *EClinicalMedicine* 2021, **40**:101099.


- 660 26. Douillard V, Castelli EC, Mack SJ, Hollenbach JA, Gourraud PA, Vince N, Limou S, Covid,
661 Hla, Immunogenetics C, et al.: **Current HLA Investigations on SARS-CoV-2 and**
662 **Perspectives.** *Front Genet* 2021, **12**:774922.
- 663 27. Kreutmair S, Unger S, Nunez NG, Ingelfinger F, Alberti C, De Feo D, Krishnarajah S,
664 Kauffmann M, Friebel E, Babaei S, et al.: **Distinct immunological signatures**
665 **discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.**
666 *Immunity* 2021, **54**:1578-1593 e1575.
- 667 28. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, Chen PJ, Su YW, Lim KH, Tsai ZU,
668 et al.: **Association of HLA class I with severe acute respiratory syndrome**
669 **coronavirus infection.** *BMC Med Genet* 2003, **4**:9.
- 670 29. Iturrieta-Zuazo I, Rita CG, Garcia-Soidan A, de Malet Pintos-Fonseca A, Alonso-Alarcon N,
671 Pariente-Rodriguez R, Tejeda-Velarde A, Serrano-Villar S, Castaner-Alabau JL, Nieto-
672 Ganan I: **Possible role of HLA class-I genotype in SARS-CoV-2 infection and**
673 **progression: A pilot study in a cohort of Covid-19 Spanish patients.** *Clin Immunol*
674 *2020*, **219**:108572.
- 675 30. Agerer B, Koblishke M, Gudipati V, Montano-Gutierrez LF, Smyth M, Popa A, Genger JW,
676 Endler L, Florian DM, Muhlgrabner V, et al.: **SARS-CoV-2 mutations in MHC-I-**
677 **restricted epitopes evade CD8(+) T cell responses.** *Sci Immunol* 2021, **6**.
- 678 31. Martin-Sancho L, Lewinski MK, Pache L, Stoneham CA, Yin X, Becker ME, Pratt D, Churas
679 C, Rosenthal SB, Liu S, et al.: **Functional landscape of SARS-CoV-2 cellular**
680 **restriction.** *Mol Cell* 2021.
- 681 32. Nemudryi A, Nemudraia A, Wiegand T, Nichols J, Snyder DT, Hedges JF, Cicha C, Lee H,
682 Vanderwood KK, Bimczok D, et al.: **SARS-CoV-2 genomic surveillance identifies**
683 **naturally occurring truncation of ORF7a that limits immune suppression.** *Cell Rep*
684 *2021*:109197.
- 685 33. Nelson CA, Pekosz A, Lee CA, Diamond MS, Fremont DH: **Structure and intracellular**
686 **targeting of the SARS-coronavirus Orf7a accessory protein.** *Structure* 2005, **13**:75-
687 85.
- 688 34. Zhang J, Cruz-Cosme R, Zhuang MW, Liu D, Liu Y, Teng S, Wang PH, Tang Q: **A systemic**
689 **and molecular study of subcellular localization of SARS-CoV-2 proteins.** *Signal*
690 *Transduct Target Ther* 2020, **5**:269.
- 691 35. Giraudo CG, Maccioni HJ: **Endoplasmic reticulum export of glycosyltransferases**
692 **depends on interaction of a cytoplasmic dibasic motif with Sar1.** *Mol Biol Cell* 2003,
693 **14**:3753-3766.
- 694 36. Ujike M, Huang C, Shirato K, Makino S, Taguchi F: **The contribution of the cytoplasmic**
695 **retrieval signal of severe acute respiratory syndrome coronavirus to intracellular**
696 **accumulation of S proteins and incorporation of S protein into virus-like particles.**
697 *J Gen Virol* 2016, **97**:1853-1864.
- 698 37. Taylor JK, Coleman CM, Postel S, Sisk JM, Bernbaum JG, Venkataraman T, Sundberg EJ,
699 Frieman MB: **Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits**
700 **Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of**
701 **Glycosylation Interference.** *J Virol* 2015, **89**:11820-11833.
- 702 38. Stewart H, Johansen K, McGovern N, Palmulli R, Carnell G, Heeney J, Okkenhaug K, Firth
703 A, Peden A, Edgar J: **SARS-CoV-2 spike downregulates tetherin to enhance viral**
704 **spread.** *bioRxiv* 2021:2021.2001.2006.425396.
- 705 39. Rohde J, Emschermann F, Knittler MR, Rziha HJ: **Orf virus interferes with MHC class I**
706 **surface expression by targeting vesicular transport and Golgi.** *BMC Vet Res* 2012,
707 **8**:114.
- 708 40. Hansen MD, Johnsen IB, Stiberg KA, Sherstova T, Wakita T, Richard GM, Kandasamy RK,
709 Meurs EF, Anthonsen MW: **Hepatitis C virus triggers Golgi fragmentation and**

- 710 **autophagy through the immunity-related GTPase M.** *Proc Natl Acad Sci U S A* 2017,
711 **114:**E3462-E3471.
- 712 41. Mousnier A, Swieboda D, Pinto A, Guedan A, Rogers AV, Walton R, Johnston SL, Solari R:
713 **Human rhinovirus 16 causes Golgi apparatus fragmentation without blocking**
714 **protein secretion.** *J Virol* 2014, **88:**11671-11685.
- 715 42. Freundt EC, Yu L, Goldsmith CS, Welsh S, Cheng A, Yount B, Liu W, Frieman MB,
716 Buchholz UJ, Screaton GR, et al.: **The open reading frame 3a protein of severe acute**
717 **respiratory syndrome-associated coronavirus promotes membrane rearrangement**
718 **and cell death.** *J Virol* 2010, **84:**1097-1109.
- 719 43. Morito D, Nagata K: **Pathogenic Hijacking of ER-Associated Degradation: Is ERAD**
720 **Flexible?** *Mol Cell* 2015, **59:**335-344.
- 721 44. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL:
722 **Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum**
723 **to the proteasome for destruction.** *Nature* 1996, **384:**432-438.
- 724 45. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL: **The human**
725 **cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the**
726 **endoplasmic reticulum to the cytosol.** *Cell* 1996, **84:**769-779.
- 727 46. Stagg HR, Thomas M, van den Boomen D, Wiertz EJ, Drabkin HA, Gemmill RM, Lehner PJ:
728 **The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from**
729 **the ER.** *J Cell Biol* 2009, **186:**685-692.
- 730 47. Soetandyo N, Ye Y: **The p97 ATPase dislocates MHC class I heavy chain in US2-**
731 **expressing cells via a Ufd1-Npl4-independent mechanism.** *J Biol Chem* 2010,
732 **285:**32352-32359.
- 733 48. van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, Kremmer E, Hoeben
734 RC, LeProust EM, Chen S, Hoelen H, et al.: **A high-coverage shRNA screen**
735 **identifies TMEM129 as an E3 ligase involved in ER-associated protein**
736 **degradation.** *Nat Commun* 2014, **5:**3832.
- 737 49. van den Boomen DJ, Timms RT, Grice GL, Stagg HR, Skodt K, Dougan G, Nathan JA,
738 Lehner PJ: **TMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-**
739 **induced degradation of MHC-I.** *Proc Natl Acad Sci U S A* 2014, **111:**11425-11430.
- 740 50. Ye Y, Meyer HH, Rapoport TA: **The AAA ATPase Cdc48/p97 and its partners transport**
741 **proteins from the ER into the cytosol.** *Nature* 2001, **414:**652-656.
- 742 51. Moriyama M, Lucas C, Monteiro VS, Yale S-C-GSI, Iwasaki A: **SARS-CoV-2 variants do**
743 **not evolve to promote further escape from MHC-I recognition.** *bioRxiv* 2022.
- 744 52. Yoo JS, Sasaki M, Cho SX, Kasuga Y, Zhu B, Ouda R, Orba Y, de Figueiredo P, Sawa H,
745 Kobayashi KS: **SARS-CoV-2 inhibits induction of the MHC class I pathway by**
746 **targeting the STAT1-IRF1-NLRC5 axis.** *Nat Commun* 2021, **12:**6602.
- 747 53. Nizamudeen ZA, Xu ER, Karthik V, Halawa M, Arkill KP, Jackson AM, Bates DO, Emsley J:
748 **Structural assessment of SARS-CoV2 accessory protein ORF7a predicts LFA-1**
749 **and Mac-1 binding potential.** *Biosci Rep* 2021, **41.**
- 750 54. Hanel K, Willbold D: **SARS-CoV accessory protein 7a directly interacts with human**
751 **LFA-1.** *Biol Chem* 2007, **388:**1325-1332.
- 752 55. Walling BL, Kim M: **LFA-1 in T Cell Migration and Differentiation.** *Front Immunol* 2018,
753 **9:**952.
- 754 56. Bui TM, Wiesolek HL, Sumagin R: **ICAM-1: A master regulator of cellular responses in**
755 **inflammation, injury resolution, and tumorigenesis.** *J Leukoc Biol* 2020, **108:**787-
756 799.
- 757 57. Holland LA, Kaelin EA, Maqsood R, Estifanos B, Wu LI, Varsani A, Halden RU, Hogue BG,
758 Scotch M, Lim ES: **An 81-Nucleotide Deletion in SARS-CoV-2 ORF7a Identified from**
759 **Sentinel Surveillance in Arizona (January to March 2020).** *J Virol* 2020, **94.**

- 760 58. Addetia A, Xie H, Roychoudhury P, Shrestha L, Loprieno M, Huang ML, Jerome KR,
761 Greninger AL: **Identification of multiple large deletions in ORF7a resulting in in-**
762 **frame gene fusions in clinical SARS-CoV-2 isolates.** *J Clin Virol* 2020, **129**:104523.
763 59. Rosenthal SH, Kagan RM, Gerasimova A, Anderson B, Grover D, Hua M, Liu Y, Owen R,
764 Lacbawan F: **Identification of eight SARS-CoV-2 ORF7a deletion variants in 2,726**
765 **clinical specimens.** *bioRxiv* 2020:2020.2012.2010.418855.
766 60. Tan Y, Schneider T, Leong M, Aravind L, Zhang D: **Novel Immunoglobulin Domain**
767 **Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-**
768 **Related Viruses.** *mBio* 2020, **11**.
769 61. Neches RY, Kyrpides NC, Ouzounis CA: **Atypical Divergence of SARS-CoV-2 Orf8 from**
770 **Orf7a within the Coronavirus Lineage Suggests Potential Stealthy Viral Strategies**
771 **in Immune Evasion.** *mBio* 2021, **12**.
772 62. Young BE, Fong SW, Chan YH, Mak TM, Ang LW, Anderson DE, Lee CY, Amrun SN, Lee
773 B, Goh YS, et al.: **Effects of a major deletion in the SARS-CoV-2 genome on the**
774 **severity of infection and the inflammatory response: an observational cohort**
775 **study.** *Lancet* 2020, **396**:603-611.
776 63. Zinzula L: **Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2.** *Biochem*
777 *Biophys Res Commun* 2021, **538**:116-124.
778 64. Flower TG, Buffalo CZ, Hooy RM, Allaire M, Ren X, Hurley JH: **Structure of SARS-CoV-2**
779 **ORF8, a rapidly evolving coronavirus protein implicated in immune evasion.**
780 *bioRxiv* 2020.
781 65. Arshad N, Laurent-Rolle M, Ahmed WS, Hsu JC, Mitchell SM, Pawlak J, Sengupta D,
782 Biswas KH, Cresswell P: **SARS-CoV-2 accessory proteins ORF7a and ORF3a use**
783 **distinct mechanisms to downregulate MHC-I surface expression.** *bioRxiv* 2022.
784 66. Zhang F, Zang T, Stevenson EM, Lei X, Copertino DC, Mota TM, Boucau J, Garcia-Beltran
785 WF, Jones B, Bieniasz PD: **Inhibition of major histocompatibility complex-I antigen**
786 **presentation by sarbecovirus ORF7a proteins.** *bioRxiv* 2022.

787


788 **Figures**
789



790

791 **Figure 1. SARS-CoV-2 infection causes downregulation of surface MHC class I levels in Vero E6 and A549 cells.**

792 (A) Vero E6 cells were infected with SARS-CoV-2 strain NL/2020 (MOI 0.01) and analyzed for surface MHC class I
793 levels by flow cytometry at 1 and 2 dpi. Spike antibody stains were included to allow discrimination between SARS-
794 CoV-2 infected (infected, black filled histograms) and non-infected cells present in the same culture (gray
795 histograms). Unstained cells are indicated (open histograms). (B) same as in A), yet A549-ACE2-TMPRSS2 cells were
796 infected with SARS-CoV-2 strain NL/2020 at an MOI of 0.5. For human cells HLA-I nomenclature was used instead of
797 MHC-I



798

799

Figure 2. SARS-CoV-2 ORF7a causes downregulation of cell surface HLA class I levels.

800

(A) Schematic overview of the screen to assess which SARS-CoV-2 cDNAs causes downregulation of cell surface HLA-

801

class I levels in 293T cells. (B) Indicated SARS-CoV-2 cDNAs were introduced in 293T cells by lentiviral transduction

802

and selected to purity. HLA class I protein surface levels were subsequently assessed by flow cytometry using an

803

anti-HLA-I antibody (W6/32). Relative surface HLA-I levels as compared to non-transduced cells (wt) are presented.

804

One-way ANOVA with Tukey's multiple comparisons test for $n = 2$. P value ORF7a = 0,0011, rest not significant. (C)


805

Flow cytometry analysis of surface HLA-I expression levels of 293T cells transduced with lentiviral vectors encoding

806

SARS-CoV-2 ORF7a, ORF7a-StrepII, ORF8-StrepII, or empty vector control (EV) at 7 dpi. The cDNA vectors co-express

807 the mAmetrine-fluorescent protein to allow discrimination between transduced (mAmetrine-positive) and non-
808 transduced (mAmetrine-negative) cells within the same culture. Unstained cells are indicated (open histograms).
809 One representative figure of >5 experiments is shown. (D) Western blot analysis of StrepII-tagged proteins from C):
810 empty control vector (EV), SARS-CoV-2 ORF7a-StrepII or SARS-CoV-2 ORF8-StrepII. Transferrin receptor (TfR) protein
811 levels are presented as loading control. One representative experiment of two is shown.




812

813 **Figure 3. ORF7a specifically downregulates HLA-I from the cell surface of multiple cell types.**

814 (A) 293T cells transduced with StrepII-tagged SARS-CoV-2 cDNAs and subsequently selected to purity were stained
815 with monoclonal antibodies to detect the cell-surface expression levels of the indicated proteins. To assess whether
816 ORF7a-transduced cells showed differential cell-surface expression levels as compared to cells transduced with other
817 (non-ORF7a) SARS-CoV-2 cDNAs, we pooled all non-ORF7a-cDNA-transduced cells in the analysis (indicated as
818 'Library') and compared these with the ORF7a-transduced cells. Expression levels for each antigen were normalized
819 to stainings performed on non-transduced cells. (B) Flow cytometry analysis of surface expression levels of the
820 indicated antigens in 293T cells transduced with StrepII-tagged SARS-CoV-2 ORF7a (determined by mAmetrine
821 expression, dark gray histograms) compared to non-transduced cells (light gray histograms). Unstained cells are


822 indicated (open histograms). Cells were analyzed at 4 dpi. (C) SARS-CoV-2 ORF7a downregulates HLA-I from the
823 surface of multiple cell types. Flow cytometry analysis of surface HLA-I levels in 293T, MeJuSo, HK-1 and Huh7 cells
824 transduced with a StrepII-tagged SARS-CoV-2 ORF7a (determined by mAmetrine expression, dark gray histograms)
825 compared to non-transduced cells (light gray histograms). Unstained cells are indicated (open histograms). Cells
826 were analyzed at 6 dpi. Note that for Huh7 cells, gating on mAmetrine was not possible due to relatively low
827 expression of the fluorescent protein, therefore puromycin-selected cells (dark gray histogram) were compared with
828 stained non-transduced cells (light gray histogram). One representative experiment of three experiments is shown



829
830 **Figure 4. The ORF7a signal peptide sequence and transmembrane domain are essential for HLA-I surface**
831 **downregulation, whereas the C-terminal ER-retrieval signal is not.**

832 **(A)** Schematic representation of the SARS-CoV-2 ORF7a protein, consisting of the signal peptide sequence, luminal
833 domain, transmembrane (TM) domain and cytosolic tail, and the generated mutants CD8S-ORF7a, ORF7a Tail-mut
834 and ORF7a Δ TM/tail. **(B)** 293T cells transduced with the ORF7a mutants from A) were selected by puromycin-
835 treatment and expression levels were assessed by immunoblotting using an anti-ORF7a antibody and transferrin
836 receptor antibody (TfR) as control. **(C)** 293T cells transduced with SARS-CoV-2 ORF7a, CD8S-ORF7a, ORF7a Tail-mut,
837 ORF7a Δ TM/tail, or control vector (EV) were subjected to flow cytometry at 7 dpi to assess HLA-I cell-surface levels.
838 mAmetrine expression was used to allow for discrimination between transduced (closed dark gray histograms,
839 mAmetrine-positive) and non-transduced (light gray histograms, mAmetrine-negative) cells within the same culture.
840 Unstained cells are indicated (open histograms). One representative experiment of five is presented.

841




842

843 **Figure 5. A single amino acid substitution in SARS-CoV-1 ORF7a confers the ability to downregulate surface HLA-I**
 844 **expression.**

845 (A) Protein sequence alignment of ORF7a from SARS-CoV-2 and SARS-CoV-1 identifies three regions of variability
 846 located in the signal peptide region (I), the luminal domain (II), and the stalk/TM region (III). The location of the signal
 847 peptide and TM region is indicated. (B) Schematic representation of the signal peptide chimera, the luminal chimera

848 and the TM chimera, in which parts of the SARS-CoV-2 ORF7a sequence (indicated as open boxes) were introduced
849 in the SARS-CoV-1 ORF7a sequence (gray boxes). (C) 293T cells transduced with the ORF7a chimeras from B) were
850 subjected to flow cytometry at 6 dpi to assess HLA-I cell-surface levels. The ORF7a vector co-expresses mAmetrine
851 to allow discrimination between ORF7a-transduced (closed black histograms, mAmetrine-positive) and non-
852 transduced (open histograms, mAmetrine-negative) cells within the same culture. Unstained cells are indicated
853 (open histograms). One representative experiment of three is presented. (D) ORF7a chimera and transferrin protein
854 levels were assessed by immunoblotting of lysates from 293T cells expressing SARS-CoV-1-ORF7a, the signal peptide
855 chimera, the luminal chimera or the TM chimera from C). (E) Indicated triple, double, and single aa mutations were
856 introduced in the SARS-CoV-1 ORF7a protein. 293T cells were subsequently transduced with the chimeric molecules
857 and subjected to flow cytometry at 6 dpi to assess HLA-I cell-surface levels, as described above. Unstained 293T cells
858 are indicated (open histograms). (F) Protein sequence alignment of multiple isolates from human (SARS-CoV-1 and
859 SARS-CoV-2), pangolin, and bat sarbecoviruses. Identical residues are indicated in gray. The amino acids at position
860 59 are indicated.

861



862


863

864 **Figure 6. ORF7a induces intracellular HLA-I accumulation in the ER.**

865 (A) 293T cells transduced with ORF7a were subjected to surface and intracellular HLA-I stainings using the W6/32
 866 antibody and assessed by flow cytometry at 7 dpi. The ORF7a vector co-expresses mAmetrine to allow discrimination
 867 between ORF7a-transduced (dark gray histograms, mAmetrine-positive) and non-transduced (light gray histograms,
 868 mAmetrine-negative) cells within the same culture. Unstained cells are indicated (open histograms). One
 869 representative experiment of at least 5 experiments is presented. (B) ORF7a, HLA-I and transferrin protein levels
 870 were assessed by immunoblotting of lysates from 293T cells transduced with an empty vector control (EV) or the

871 SARS-CoV-2 ORF7a at 7 dpi; cells were selected to purity by puromycin prior to immunoblotting. **(C)** HLA-I and
872 transferrin protein levels and glycosylation status were assessed by immunoblotting of 293T cells transduced with
873 an empty control vector (EV) or ORF7a. Lysates were either left untreated or were incubated with Endo H_f or N-
874 Glycosidase F (GlcF) prior to loading. **(D)** ORF7a and HLA-I localization were assessed by immunofluorescence in
875 MeJuSo cells transduced with SARS-CoV-2 ORF7a. Nuclei were stained with DAPI. In the view, two ORF7a positive
876 cells and three non-transduced cells are apparent. In the merged image, ORF7a signal is indicated in cyan, HLA-I
877 signal in magenta, and DAPI signal in orange. The scale bar corresponds to 10 μm. Contours of cells are marked with
878 a gray line and the insets show magnifications of the indicated region.

879




880

881 **Figure 7. ORF7a-mediated surface HLA-I downregulation is abrogated upon proteasome- and p97-inhibition,**
882 **whereas intracellular HLA-I levels are unaffected.**

883 293T cells transduced with SARS-CoV-2 ORF7a or empty vector control (EV) were treated at 10 dpi with 20 μ M
884 MG132 or 4 μ M CB-5083 p97-inhibitor for 4 hours. Subsequently, cells were harvested and subjected to surface and
885 intracellular HLA-I stainings using the W6/32 antibody and analyzed by flow cytometry. The EV and ORF7a
886 transduced cells co-express mAmetrine to allow discrimination between transduced (closed black histograms,
887 mAmetrine-positive) and non-transduced (open histograms, mAmetrine-negative) cells within the same culture. One
888 representative experiment of at least 5 experiments is presented.

889



890

891 **Figure 8. ORF7a interacts with HLA class I heavy chains.**

892 StreptII-tagged proteins were immunoprecipitated by using Streptactin beads from lysates of 293T cells transduced
893 with EV or Strep-II-tagged ORF7a (StrepII IP: lanes 3 and 4). Furthermore, endogenous HLA class I molecules were
894 immunoprecipitated from the same lysates by using Protein G Sepharose beads coupled to the HC10 anti-HLA class
895 I antibody (HLA-I IP: lanes 5 and 6). Total cell lysates (TCL, lanes 1 and 2) and immunoprecipitation samples (lanes 3
896 through 6) were loaded on Western blot and stained for ORF7a, HLA class I, and TfR.